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Abstract The induction of cell death in immune cells by
naturally occurring antibodies specific for death receptors
may present an important antiinflammatory mechanism of
intravenous immunoglobulin (IVIG). Conversely, the
protection of tissue cells from death receptor-mediated
apoptosis by blocking antibodies is thought to contribute
to the beneficial effects of IVIG in certain inflammatory
disorders such as toxic epidermal necrolysis, also known
as Lyell's syndrome. In this review, we focus on recent
insights into the role of functional antibodies against Fas,
sialic acid-binding immunoglobulin-like lectin (Siglec)-8,
and Siglec-9 receptors in IVIG-mediated cell survival or death
effects. In addition, we examine a variety of factors in
inflammatory disease that may interplay with these cellular
events and influence the therapeutic efficacy or potency of
IVIG. These involve activation status of the target cell,
cytokine microenvironment, pathogenesis and stage of dis-
ease, individual genetic determinants, species characteristics,
and batch-to-batch variations of IVIG preparations.
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Introduction
Commercial intravenous immunoglobulin (IVIG) prepa-
rations are being used increasingly as a high-dose therapy
for the treatment of inflammatory diseases. In addition to its
licensed indications for Kawasaki disease, immune
thrombocytopenic purpura, Guillain–Barré syndrome,
and chronic inflammatory demyelinating polyneuropathy,
IVIG is also used as an antiinflammatory drug for
numerous off-label applications [1, 2]. Its mode of action
is complex. Although a variety of potential modes of
action have been proposed, the exact mechanisms of the
immunoregulatory effects of IVIG remain to be described,
even for approved indications. Both F(ab)- and Fc-related
mechanisms may act in a mutually nonexclusive fashion
depending on the pathogenesis of the disease [1–3].
Indeed, the multiplicity of immunoregulatory mechanisms
might explain the beneficial effects of IVIG in a broad
range of pathogenetically heterogenous inflammatory
disorders.
Derived from the pooled plasma of thousands of
donors, IVIG contains the large repertoire of antibody
specificities of the donor population [4, 5]. In addition to
antibodies with antiinfectious activity, a broad range of
naturally occurring autoantibodies with the capacity to
regulate important immune functions are present in IVIG.
Natural antibodies are thought to be implicated in
maintaining immune homeostasis in healthy individuals
and to contribute to the antiinflammatory effects of IVIG
[1, 6, 7].
Regulation of immune cells by cell death or survival is
the key for the maintenance of immune homeostasis, the
control of immune responses, and the resolution of
inflammatory processes [8–13]. Functional antibodies that
regulate the life span of inflammatory cells contained in
commercial IVIG preparations might, therefore, play an
important role for the therapeutic effects of IVIG in
inflammatory disorders. The focus of this review will be
on agonistic and antagonistic autoantibodies against the
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receptors Fas, sialic acid-binding immunoglobulin-like
lectin (Siglec)-8, and Siglec-9 contained in IVIG. Potential
counteracting or facilitating mechanisms that control the
activity of these effector molecules also will be discussed.
Fas
Programmed cell death of effector cells plays an important
role in shutting down cellular and humoral immune
responses [8–11]. In addition, apoptosis of activated
inflammatory cells minimizes the collateral damage to
healthy tissues that could be caused by immune effector
molecules [14].
Fas (also called APO-1 or CD95), a death domain-
containing member of the tumor necrosis factor receptor
family, triggers apoptotic cell death in many cell systems.
Interestingly, we found that in the short-living neutrophil
granulocytes. Fas blocks cytokine-induced antiapoptotic
signaling [15], which may prevent neutrophil accumulation
at the site of inflammation through lack of clearance [16].
In mutant mouse strains, homozygous defects in the genes
encoding Fas (Faslpr/lpr or Faslprcg/lprcg) [17] or its physio-
logical ligand FasL (FasLgld/gld) [18] are associated with
lymphadenopathy and autoimmune diseases that display
symptoms characteristic of systemic lupus erythematosus.
In addition, a large fraction of human autoimmune
lymphoproliferative syndrome patients exhibit heterozy-
gous inherited mutations in the Fas gene [19, 20]. These
findings suggest an important role of Fas in controlling
both the innate and the adaptive immune system.
Anti-Fas Autoantibodies in IVIG
Viard et al. (1998) reported that IVIG contains blocking
antibodies with the capacity to inhibit Fas-mediated
keratinocyte apoptosis in toxic epidermal necrolysis
(TEN), also known as Lyell's syndrome [21]. In contrast,
other groups reported that IVIG induces caspase-dependent
apoptosis in lymphocytes and monocytes [22, 23], gener-
ated by agonistic anti-Fas antibodies contained in IVIG
[22]. Using neutrophils as target cells, we were able to
clarify this discrepancy, showing that both agonistic and
antagonistic anti-Fas antibodies are present in IVIG and that
the effect on Fas is concentration dependent [24]. The
balance between Fas-stimulating and Fas-blocking anti-
bodies has recently been shown to vary among different
IVIG preparations [25]. Hence, the overall Fas-related
effects of IVIG may depend on the sensitivity of the target
cell toward Fas, the concentration of IVIG, and the ratio
between agonistic and antagonistic anti-Fas autoantibodies
in the preparation (Fig. 1).
Siglecs
Siglecs represent a novel family of lectins that charac-
teristically bind to sialic acid-containing carbohydrate
structures (sialoglycans) [26–30]. Siglec receptors, which
are predominantly expressed on immune cells, have
received particular attention in light of their capacity to
mediate cell death and antiproliferative effects and their
ability to regulate cellular activities [27–30]. Whereas
some Siglec members are evolutionary conserved in
mammalians, the remaining members, especially those of
the CD33-related subgroup, which includes Siglec-8 and
Siglec-9, differ in structure or expression levels depending
on the species [27–29, 31]. The nomenclature reflects the
structural differences between species: the remaining
Siglecs in humans are numbered, but in mice, they are
lettered [27]. It has been proposed that the occurrence of
multiple changes in sialobiology might have resulted in
rapid evolutionary adjustments of Siglecs [32]. The rapid
evolution of CD33-like Siglecs may have been driven by
pathogens that bind sialic acids in a process called the
“Red Queen effect” (an unremitting evolutionary arms
race between competing species, or between a pathogen
and its host) [28, 29].
Most, but not all, Siglecs possess one or more
cytoplasmic tyrosine residues located within characteris-
tic signaling-domain configurations, especially those
involved in promoting inhibitory responses such as the
immunoreceptor tyrosine-based inhibitory motifs
(ITIMs). Upon ligation of the receptor, ITIMs are
tyrosine phosphorylated and they recruit inhibitory
phosphatases, such as Src homology domain 2 (SH2)-
containing tyrosine phosphatase-1 (SHP-1), SHP-2, and
SH2-containing inositol phosphatase, which eventually
lead to inhibitory or death signals [13, 27–29]. In Siglecs,
increased tyrosine phosphorylation of these motifs also
occurs within minutes after cytokine stimulation [33, 34].
This phosphorylation event might contribute to the
cytokine dependency of Siglecs, one element of a complex
interplay between cytokine receptor and Siglec signaling
pathways [13]. The cytokine sensitivity of Siglecs may
explain their key role as regulators of immune responses
in a cytokine-rich microenvironment, such as at an
inflammation site [13].
Siglec-8
Siglec-8, which is highly expressed on human eosinophil
granulocytes and mast cells and weakly expressed on
basophils, may play an important role in allergic diseases
[12, 27]. Although one isoform with an extremely short
cytoplasmic domain without any known signaling motifs
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has been described initially, the predominant form expressed
by cells contains a longer cytoplasmic tail with a membrane-
proximal ITIM and a membrane-distal ITIM-like domain,
similar to that found in CD150 or signaling lymphocyte
activation molecule [35]. The engagement of Siglec-8 on
mast cells counteracts stimulatory signals delivered by FcεRI
cross-linking, which inhibits inflammatory mediator release
and calcium flux [36]. Little is known about the effect of
Siglec-8 on basophils.
In eosinophils, ligation of Siglec-8 with monoclonal
antibodies results in caspase, mitochondrial, and reactive
oxygen species-dependent apoptosis [37, 38]. Intriguingly,
Siglec-8-mediated eosinophil death is significantly enhanced
in the presence of cytokines, such as interleukin (IL)-5 and
granulocyte/macrophage colony-stimulating factor (GM-
CSF), both of which are known eosinophil survival factors
[38–40]. When eosinophils isolated from the lungs of
allergen-challenged allergic subjects are exposed to cyto-
kines in vivo, they also display enhanced susceptibility to
Siglec-8-mediated death [27]. Evidence suggests that this
increase of Siglec-8-induced eosinophil death in inflamma-
tory cells, compared with normal, unstimulated eosinophils,
involves the recruitment of additional, caspase-independent
death pathways [13, 38].
Eosinophil Death Mediated by Anti-Siglec-8
Autoantibodies in IVIG
Delayed eosinophil apoptosis has been observed in associ-
ation with many chronic allergic and eosinophilic inflam-
matory diseases. This mechanism may, in concert with
chemotaxis, lead to tissue accumulation of eosinophils at
the inflammation site and/or contribute to increased
eosinophil numbers in the blood, a phenomenon called
eosinophilia [10, 12, 41]. Intravenous immunoglobulin or
F(ab′)2 fragments of IVIG accelerate spontaneous eosinophil
death in a time- and concentration-dependent manner [40].
Both the efficacy and potency of this cytotoxic effect are
significantly increased in the presence of certain cytokines
and eosinophil survival factors such as IL-5 and GM-CSF
[40]. Indeed, eosinophils isolated from patients with hyper-
eosinophilic syndrome who presumably have been exposed
to IL-5 in vivo [42, 43] demonstrate increased susceptibility
for IVIG-mediated eosinophil death ex vivo [40]. Evidence
from depletion and blocking experiments revealed that
autoantibodies against Siglec-8 contained in IVIG are
responsible for the increased eosinophil cytotoxicity of
IVIG in the presence of cytokines [40]. The Siglec-8-
mediated increase of efficacy and potency of IVIG in a
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Fig. 1 Schematic representation of proposed factors influencing
IVIG-mediated cell death of a neutrophilic granulocyte as a target
cell. The efficacy and/or potency of the cytotoxic effects of IVIG
depend on the preparation being used and on characteristics of the
treated patient or species (experimental models). Engagement of Fas
or Siglec-9 by agonistic autoantibodies contained in IVIG induces cell
death in neutrophils. Batch-to-batch variations in titer and ratio of
agonistic versus antagonistic anti-Fas autoantibodies result in differ-
ential effects on Fas, which are concentration dependent. The systemic
or local cytokine profile of the patient may facilitate IVIG-induced
neutrophil death, because Siglec-9-mediated cell death is enhanced in
the presence of cytokines due to priming effects. For yet unknown
reasons, transient resistance may block Siglec-9 death pathways in a
subset of patients, depending on the stage of disease. Siglec-E, but not
Siglec-9, is expressed in mouse neutrophils
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cytokine-rich environment might explain local antiin-
flammatory effects of systemically applied IVIG and
ameliorate the situation in patients with hypereosino-
philia, in whom eosinophils are exposed to survival
factors and/or inflammatory cytokines [42, 43]. This
mechanism might contribute to the beneficial effects of
IVIG in patients with Churg–Strauss syndrome [44–46]
and in other eosinophilic patients.
Siglec-9
Siglec-9 is highly expressed on human neutrophil
granulocytes and monocytes; however, it is expressed at
lower levels on subpopulations of lymphocytes [27]. In
neutrophils and monocytes, as well as in transfected cell
lines, ligation of Siglec-9 has been shown to result in
inhibition of cellular activities or even cell death [33, 47–
49]. Siglec-9, like Siglec-8, contains a membrane-
proximal ITIM and a membrane-distal ITIM-like domain.
The recruitment of the inhibitory phosphatases SHP-1 and
SHP-2 as a result of tyrosine phosphorylation is thought to
contribute to the inhibitory and death-promoting functions
of Siglec-9 [13, 33, 34, 47, 48].
Immature human neutrophils gain Siglec-9 surface
expression late in differentiation, appearing after the
myelocyte stage but before the expression of CD16 [33].
In cultures of mature neutrophils in vitro, ligation of
Siglec-9 by a monoclonal antibody induces caspase-
dependent apoptosis at a rate similar to that of Fas [33,
50]. Compared with Siglec-8-mediated death of eosino-
phils, Siglec-9-mediated neutrophil death is dramatically
enhanced in inflammatory neutrophils, such as cells after
priming with proinflammatory cytokines in vitro or
activated cells ex vivo from inflammatory diseases like
sepsis or rheumatoid arthritis [33]. The accelerated death
that occurs in the presence of cytokines turns out to
involve additional caspase-independent molecular path-
ways that include reactive oxygen species [33].
Neutrophil Death Induced by Anti-Siglec-9
Autoantibodies Contained in IVIG
Paralleling the reported effects of Siglec-9 on eosinophils
mentioned above, IVIG induces death of neutrophil
granulocytes in a F(ab′)2-dependent manner. This effect
dramatically accelerates in the presence of proinflammatory
cytokines such as GM-CSF and interferon-γ [51]. Intrave-
nous immunoglobulin-mediated death in the presence of
cytokines involves reactive oxygen species and caspase-
dependent and caspase-independent pathways. This process
is comparable to that which occurs after ligation of Siglec-9
by a monoclonal antibody under similar conditions, as
mentioned above [33, 51]. In depletion experiments, we
showed that anti-Siglec-9 autoantibodies contained in IVIG
are responsible for this cytokine-dependent cytotoxicity
[33].
The increased neutrophil cytotoxicity of IVIG in a
cytokine-rich environment may contribute to the antiin-
flammatory effects of IVIG in the broad range of
inflammatory diseases associated with causative neutrophil
participation. However, we observed that septic shock
patients exhibit different ex vivo death responses of blood
neutrophils after Siglec-9 ligation early in shock [50]. Both
the initial resistance and the increased susceptibility to
Siglec-9-mediated neutrophil death were reversible and
approached normal levels in the latter course of disease.
These findings suggest that in disease, Siglec-9-dependent
effects of IVIG may vary according to the disease stage and
patient characteristics (Fig. 1).
Factors Influencing IVIG-Mediated Cell Death
Responses
The capacity of IVIG to induce or prevent cell death
depends on multiple factors, determined by characteristics
of the recipient and properties of the IVIG preparation used
(Fig. 1). For instance, batch-to-batch variations of specific
antibody titers and the ratio between agonistic and
antagonistic antibodies in commercial IVIG preparations
may result in dissimilar pharmacological effects [4, 25, 52].
Recently, we obtained experimental evidence that indicates
the presence of antiidiotypic antibodies against immuno-
regulatory autoantibodies in commercial IVIG preparations.
These antiidiotypic antibodies, in concert with antagonistic
antibodies, may counter-regulate the effects of agonistic
antibodies directed against death receptors (unpublished
results).
Patient-dependent factors that may influence the antiin-
flammatory actions of IVIG include the pathogenesis,
severity and stage of disease, the individual cytokine profile
(either systemically in the blood or locally at the site of
inflammation), and other genetic determinants. The obser-
vation that the efficacy and potency of the cytotoxic effects
of IVIG are enhanced on inflammatory granulocytes
compared with normal granulocytes [40, 51] indicates that
the activation status of the target cell may significantly
influence its response to IVIG. Resistance or susceptibility
to immunoregulatory stimuli, as observed for Siglec-9 in
different patient subpopulations and in various stages of
disease [50], may greatly affect the response of immune
cells following IVIG exposure. The reason for IVIG-
induced neutropenia in some patients remains unknown
[53–57]. It has been speculated that agonistic anti-Siglec-9
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autoantibodies might cause neutropenia in patients with
increased cytokine levels [58, 59].
As discussed above, there are no exact Siglec-8 and
Siglec-9 orthologs in the mouse [27–29]. The most likely
paralogs of Siglec-8 and Siglec-9 in the mouse are Siglec-F
and Siglec-E, respectively. However, these receptors
exhibit no identical expression patterns on leukocyte
subtypes [27]. Intravenous immunoglobulin-mediated
effects on neutrophil and eosinophil granulocytes may
therefore be underestimated in conventional animal studies,
because human anti-Siglec-8 and anti-Siglec-9 autoantibodies
are not able to exert specific functions in such experimental
models (Fig. 1).
Conclusions
The broad range of inflammatory disorders for which IVIG
has shown therapeutic effects suggests that differential
antiinflammatory mechanisms of action might more or less
be effective, depending on the pathogenesis of a certain
disease. It is possible that multiple mechanisms may act in
concert and in a mutually nonexclusive manner [1]. For
instance, blocking antibodies against Fas may interfere with
FasL-induced keratinocyte apoptosis in TEN, whereas their
agonistic counterparts might down-regulate immune
responses by Fas-dependent apoptosis of immune effector
cells. Although we have focused on the death-inducing
effects of anti-Siglec and anti-Fas antibodies in receptor-
expressing cells, it is possible to speculate that these
functional antibodies may trigger additional immunoregu-
latory functions [8, 27–30].
The insights on IVIG-mediated cell death may have
several implications for future studies on the mechanisms of
action of IVIG. For instance, it was shown that cellular
responses to IVIG might differ significantly between
inflammatory and normal cells; this may be a consideration
for future functional experiments. Furthermore, it is implicit
that experimental evidence needs to be confirmed in a
human system. Certain surface receptors or effector
molecules of the immune system, such as the Siglecs,
exhibit significant species-specific differences in terms of
function, structure, or expression pattern. Although animal
experiments may provide a powerful means of studying
disease-specific mechanisms of IVIG in vivo, uncertainties
remain about the use of xenogenic (human-pooled) immu-
noglobulin in animals in terms of potential loss-of-function
or gain-of-function effects.
In this review, we emphasized that several independent
factors, including batch-to-batch variations of IVIG prepa-
rations, pathogenesis, and stage of disease, and other
patient characteristics may influence the efficacy of IVIG
treatment. These factors may also explain the discrepancies
between certain clinical studies regarding the therapeutic
effects of IVIG. Certainly, a better understanding of the
mechanisms of action is required, which will help to
improve IVIG therapy in inflammatory diseases and to
identify the patient subpopulations that are likely to profit
the most from this drug.
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